| Amrinone | heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Sudden death | no data | | Worsening heart failure | 0.74 [0.19 2.79] | p=1.00 | 0 | 99 | 1 | AMTG, | | Transplantation | no data | | Arrhythmia | no data | | Vertigo | no data | | Death from any cause or hospitalization for heart failure | no data | | myocardial infarction (fatal and non fatal) | no data | | cardiac death | no data | | All cause death | 1.11 [0.15 8.18] | p=1.00 | 0 | 99 | 1 | AMTG, |
| Trial | Studied treatment | Control | Patients |
|---|
| AMTG, 1985 | Amrinone <600mg/day | placebo | patients with heart failure NYHA III/IV |
| |
| Enoximone | heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Sudden death | 1.53 [0.34 6.90] | p=1.00 | 0 | 266 | 2 | WESG, EMTG, | | Worsening heart failure | 0.91 [0.30 2.73] | p=1.00 | 0 | 102 | 1 | EMTG, | | Transplantation | no data | | Arrhythmia | 1.50 [0.06 37.80] | p=1.00 | 0 | 105 | 1 | ESG, | | Vertigo | 0.52 [0.09 2.97] | p=1.00 | 0 | 102 | 1 | EMTG, | | Death from any cause or hospitalization for heart failure | 0.97 [0.84 1.12] | p=1.00 | 0 | 904 | 1 | ESSENTIAL (I and II), | | myocardial infarction (fatal and non fatal) | 3.12 [0.12 78.45] | p=1.00 | 0 | 102 | 1 | EMTG, | | cardiac death | 1.78 [0.93 3.40] | p=1.00 | 0 | 253 | 2 | EMTG, Cowley, | | All cause death | 1.00 [0.88 1.14] | p=1.00 | 0 | 1918 | 6 | WESG, EMTG, ESG, Lardoux, ESSENTIAL (I and II), Cowley, |
| Trial | Studied treatment | Control | Patients |
|---|
| WESG, 1991 | Enoximone 150, 300 mg/d | placebo | NYHA II, III | | EMTG, 1990 | Enoximone <450 mg/d | placebo | NYHA II, III | | ESG, 2000 | Enoximone 75-150 mg/d | placebo | NYHA II, III | | Lardoux, 1987 | Enoximone 150, 300mg/d | placebo | NYHA NA | | ESSENTIAL (I and II), 2009 | enoximone titrated to 50 mg three times daily | placebo | Patients with New York Heart Association class III–IV HF symptoms, left ventricular
ejection fraction 30%, and one hospitalization or two ambulatory visits for worsening HF in the previous
year | | Cowley, 1994 | Enoximone 300mg/d | placebo | NYHA III,IV | | EMOTE, 2007 | enoximone | placebo | patients with ultra-advanced heart failure requiring IV inotropic therapy |
| |
| Flosequinan | heart failure, in all type of patients | vs placebo | Arrhythmia by 236% suggested Vertigo by 99% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Sudden death | 1.23 [0.34 4.50] | p=1.00 | 0 | 650 | 3 | Cowley, FACET, REFLECT, | | Worsening heart failure | 0.90 [0.52 1.57] | p=1.00 | 0 | 650 | 3 | Cowley, FACET, REFLECT, | | Transplantation | no data | | Arrhythmia | 3.36 [1.06 10.65] | p=0.04 | 0 | 515 | 2 | FACET, REFLECT, | | Vertigo | 1.99 [1.03 3.84] | p=0.04 | 0 | 515 | 2 | FACET, REFLECT, | | Death from any cause or hospitalization for heart failure | no data | | myocardial infarction (fatal and non fatal) | 1.61 [0.26 9.87] | p=1.00 | 0 | 193 | 1 | REFLECT, | | cardiac death | no data | | All cause death | 1.36 [0.71 2.61] | p=1.00 | 0 | 961 | 4 | Cowley, FACET, REFLECT, REFLECT II, |
| Trial | Studied treatment | Control | Patients |
|---|
| Cowley, 1993 | Flosequinan 125mg/d | placebo | NYHA II, III | | FACET, 1993 | Flosequinan 100 and 150 mg/d | placebo | NYHA II, III | | REFLECT, 1993 | Flosequinan 100mg/d | placebo | NYHA II,III | | REFLECT II, 1991 | Flosequinan 100, 150 mg/d | | NYHA II-IV |
| |
| Ibopamine | heart failure, in all type of patients | vs placebo | Sudden death by 50% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Sudden death | 1.50 [1.02 2.20] | p=0.04 | 0 | 1906 | 1 | PRIME II, | | Worsening heart failure | no data | | Transplantation | 0.95 [0.52 1.75] | p=1.00 | 0 | 1906 | 1 | PRIME II, | | Arrhythmia | no data | | Vertigo | no data | | Death from any cause or hospitalization for heart failure | no data | | myocardial infarction (fatal and non fatal) | no data | | cardiac death | 0.71 [0.37 1.39] | p=1.00 | 0 | 1906 | 1 | PRIME II, | | All cause death | 1.20 [0.97 1.49] | p=1.00 | 0 | 1906 | 1 | PRIME II, |
| Trial | Studied treatment | Control | Patients |
|---|
| PRIME II, 1997 | oral ibopamine 100 mg three times daily | placebo | patients with heart failure NYHA III-IV |
| |
| Milrinone | heart failure, in all type of patients | vs placebo | Sudden death by 57% suggested Vertigo by 91% suggested myocardial infarction (fatal and non fatal) by 492% suggested cardiac death by 33% suggested All cause death by 30% suggested | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Sudden death | 1.57 [1.09 2.27] | p=0.04 | 0 | 1088 | 1 | PROMISE, | | Worsening heart failure | 1.04 [0.62 1.74] | p=1.00 | 0 | 1318 | 2 | PROMISE, MMTG, | | Transplantation | 0.63 [0.10 3.76] | p=1.00 | 0 | 1088 | 1 | PROMISE, | | Arrhythmia | 1.28 [0.97 1.71] | p=1.00 | 0 | 1318 | 2 | PROMISE, MMTG, | | Vertigo | 1.91 [1.37 2.67] | p=0.04 | 0 | 1318 | 2 | PROMISE, MMTG, | | Death from any cause or hospitalization for heart failure | no data | | myocardial infarction (fatal and non fatal) | 5.92 [1.05 33.30] | p=0.04 | 0 | 1318 | 2 | PROMISE, MMTG, | | cardiac death | 1.33 [1.02 1.74] | p=0.04 | 0 | 1318 | 2 | PROMISE, MMTG, | | All cause death | 1.30 [1.00 1.68] | p=0.04 | 0 | 1318 | 2 | PROMISE, MMTG, |
| Trial | Studied treatment | Control | Patients |
|---|
| PROMISE, 1991 | Milrinone 40mg/d | placebo | NYHA III,IV | | MMTG, 1989 | Milrinone <40mg/d | placebo | NYHA II-IV |
| |
| Vesnarinone | heart failure, in all type of patients | vs placebo | all NS | | Endpoint | TE [95% CI] | p val | I2 | n | k | |
|---|
| Sudden death | 1.19 [0.95 1.48] | p=1.00 | 0 | 4310 | 2 | VEST, VSG, | | Worsening heart failure | 0.91 [0.79 1.05] | p=1.00 | 0 | 4393 | 3 | OPC-8212 MRG, VEST, VSG, | | Transplantation | 0.46 [0.17 1.23] | p=1.00 | 0 | 477 | 1 | VSG, | | Arrhythmia | 2.83 [0.44 18.13] | p=1.00 | 0 | 560 | 2 | OPC-8212 MRG, VSG, | | Vertigo | 2.53 [0.10 64.06] | p=1.00 | 0 | 83 | 1 | OPC-8212 MRG, | | Death from any cause or hospitalization for heart failure | no data | | myocardial infarction (fatal and non fatal) | 1.21 [0.56 2.59] | p=1.00 | 0 | 4310 | 2 | VEST, VSG, | | cardiac death | 1.06 [0.89 1.25] | p=1.00 | 0 | 4310 | 2 | VEST, VSG, | | All cause death | 1.09 [0.92 1.28] | p=1.00 | 0 | 4393 | 3 | OPC-8212 MRG, VEST, VSG, |
| Trial | Studied treatment | Control | Patients |
|---|
| OPC-8212 MRG, 1990 | Vesnarinone 60mg/d | placebo | NYHA II-IV | | VEST, 1998 | Vesnarinone 30, 60mg/d | placebo | NYHA III,IV | | VSG, 1993 | Vesnarinone 60mg/d | placebo | NYHA II-IV |
| |
